FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016741819> ?p ?o ?g. }

• W2016741819 endingPage "87" @default.
• W2016741819 startingPage "87" @default.
• W2016741819 abstract "Restenosis after percutaneous transluminal angioplasty (PTA) of the superficial femoral artery (SFA) may occur in 45% of patients at 2 years follow-up. Paclitaxel-coated balloons have been found to reduce neointimal hyperplasia, and thus reduce restenosis. Recently, the Legflow(®) paclitaxel-coated balloon (Cardionovum Sp.z.o.o., Warsaw, Poland) (LPEB) has been introduced. This balloon is covered with shellac, a Food and Drug Administration (FDA) approved natural resin, to obtain an equally distributed tissue concentration of paclitaxel. The RAPID trial is designed to assess restenosis after PTA using the Legflow balloon combined with nitinol stenting versus uncoated balloons with nitinol stenting in SFA lesions >5 cm.A total of 176 adult patients with Rutherford class 2 to class 6 symptoms due to intermediate (5-15 cm) or long (>15 cm) atherosclerotic lesions in the SFA will be randomly allocated for treatment with LPEB with nitinol stenting or uncoated balloon angioplasty with stenting. Stenting will be performed using the Supera(®) stent in both groups (IDEV Technologies Inc., Webster, TX). The primary endpoint is the absence of binary restenosis of the treated SFA segment. Secondary outcomes are target lesion revascularization (TLR), clinical and hemodynamic outcome, amputation rate, mortality rate, adverse events, and device-specific adverse events. Follow up consists of four visits in which ankle-brachial indices (ABI), toe pressure measurements, and duplex ultrasound (DUS) will be performed. Furthermore, a peripheral artery questionnaire (PAQ) will be completed by the patients at each follow-up. In the event that DUS reveals a symptomatic >50% restenosis, or a >75% asymptomatic restenosis, additional digital subtraction angiography will be performed with any necessary re-intervention.The RAPID trial is a multicenter randomized controlled patient blind trial that will provide evidence concerning whether the use of the Legflow paclitaxel/shellac coated balloons with nitinol stenting significantly reduces the frequency of restenosis in intermediate and long SFA lesions compared to standard PTA and stenting.ISRCTN47846578." @default.
• W2016741819 created "2016-06-24" @default.
• W2016741819 creator A5005965676 @default.
• W2016741819 creator A5009172577 @default.
• W2016741819 creator A5018585563 @default.
• W2016741819 creator A5036799955 @default.
• W2016741819 creator A5040187705 @default.
• W2016741819 creator A5057728985 @default.
• W2016741819 creator A5060911999 @default.
• W2016741819 creator A5070446099 @default.
• W2016741819 creator A5074394871 @default.
• W2016741819 creator A5088907234 @default.
• W2016741819 creator A5091907247 @default.
• W2016741819 date "2013-01-01" @default.
• W2016741819 modified "2023-09-28" @default.
• W2016741819 title "Randomized trial of Legflow® paclitaxel eluting balloon and stenting versus standard percutaneous transluminal angioplasty and stenting for the treatment of intermediate and long lesions of the superficial femoral artery (RAPID trial): study protocol for a randomized controlled trial" @default.
• W2016741819 cites W1536737910 @default.
• W2016741819 cites W1976235521 @default.
• W2016741819 cites W2008850799 @default.
• W2016741819 cites W2030044972 @default.
• W2016741819 cites W2053403042 @default.
• W2016741819 cites W2062321446 @default.
• W2016741819 cites W2109322281 @default.
• W2016741819 cites W2116161527 @default.
• W2016741819 cites W2132880199 @default.
• W2016741819 cites W2133288221 @default.
• W2016741819 cites W2155892833 @default.
• W2016741819 doi "https://doi.org/10.1186/1745-6215-14-87" @default.
• W2016741819 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3651710" @default.
• W2016741819 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23537403" @default.
• W2016741819 hasPublicationYear "2013" @default.
• W2016741819 type Work @default.
• W2016741819 sameAs 2016741819 @default.
• W2016741819 citedByCount "14" @default.
• W2016741819 countsByYear W20167418192014 @default.
• W2016741819 countsByYear W20167418192015 @default.
• W2016741819 countsByYear W20167418192016 @default.
• W2016741819 countsByYear W20167418192017 @default.
• W2016741819 countsByYear W20167418192018 @default.
• W2016741819 countsByYear W20167418192020 @default.
• W2016741819 countsByYear W20167418192021 @default.
• W2016741819 countsByYear W20167418192022 @default.
• W2016741819 crossrefType "journal-article" @default.
• W2016741819 hasAuthorship W2016741819A5005965676 @default.
• W2016741819 hasAuthorship W2016741819A5009172577 @default.
• W2016741819 hasAuthorship W2016741819A5018585563 @default.
• W2016741819 hasAuthorship W2016741819A5036799955 @default.
• W2016741819 hasAuthorship W2016741819A5040187705 @default.
• W2016741819 hasAuthorship W2016741819A5057728985 @default.
• W2016741819 hasAuthorship W2016741819A5060911999 @default.
• W2016741819 hasAuthorship W2016741819A5070446099 @default.
• W2016741819 hasAuthorship W2016741819A5074394871 @default.
• W2016741819 hasAuthorship W2016741819A5088907234 @default.
• W2016741819 hasAuthorship W2016741819A5091907247 @default.
• W2016741819 hasBestOaLocation W20167418191 @default.
• W2016741819 hasConcept C126322002 @default.
• W2016741819 hasConcept C126838900 @default.
• W2016741819 hasConcept C139059822 @default.
• W2016741819 hasConcept C141071460 @default.
• W2016741819 hasConcept C168563851 @default.
• W2016741819 hasConcept C203092338 @default.
• W2016741819 hasConcept C2778095995 @default.
• W2016741819 hasConcept C2778283817 @default.
• W2016741819 hasConcept C2778583881 @default.
• W2016741819 hasConcept C2778620186 @default.
• W2016741819 hasConcept C2780326628 @default.
• W2016741819 hasConcept C2780400711 @default.
• W2016741819 hasConcept C2780813298 @default.
• W2016741819 hasConcept C2781464078 @default.
• W2016741819 hasConcept C500558357 @default.
• W2016741819 hasConcept C535046627 @default.
• W2016741819 hasConcept C71924100 @default.
• W2016741819 hasConceptScore W2016741819C126322002 @default.
• W2016741819 hasConceptScore W2016741819C126838900 @default.
• W2016741819 hasConceptScore W2016741819C139059822 @default.
• W2016741819 hasConceptScore W2016741819C141071460 @default.
• W2016741819 hasConceptScore W2016741819C168563851 @default.
• W2016741819 hasConceptScore W2016741819C203092338 @default.
• W2016741819 hasConceptScore W2016741819C2778095995 @default.
• W2016741819 hasConceptScore W2016741819C2778283817 @default.
• W2016741819 hasConceptScore W2016741819C2778583881 @default.
• W2016741819 hasConceptScore W2016741819C2778620186 @default.
• W2016741819 hasConceptScore W2016741819C2780326628 @default.
• W2016741819 hasConceptScore W2016741819C2780400711 @default.
• W2016741819 hasConceptScore W2016741819C2780813298 @default.
• W2016741819 hasConceptScore W2016741819C2781464078 @default.
• W2016741819 hasConceptScore W2016741819C500558357 @default.
• W2016741819 hasConceptScore W2016741819C535046627 @default.
• W2016741819 hasConceptScore W2016741819C71924100 @default.
• W2016741819 hasIssue "1" @default.
• W2016741819 hasLocation W20167418191 @default.
• W2016741819 hasLocation W20167418192 @default.
• W2016741819 hasLocation W20167418193 @default.
• W2016741819 hasLocation W20167418194 @default.
• W2016741819 hasLocation W20167418195 @default.
• W2016741819 hasLocation W20167418196 @default.
• W2016741819 hasOpenAccess W2016741819 @default.
• W2016741819 hasPrimaryLocation W20167418191 @default.

• next